Double Blind Randomized Trial to Compare Gurmar (Gymnema Sylvestre) With Metformin in Type 2 Diabetes

This study is not yet open for participant recruitment.

Verified by Postgraduate Institute of Medical Education and Research, November 2006

First Received: November 6, 2006 No Changes Posted

Sponsor:	Postgraduate Institute of Medical Education and Research
Collaborators:	Indian Council of Medical Research International Clinical Epidemiology Network (INCLEN) TRUST
Information provided by:	Postgraduate Institute of Medical Education and Research
ClinicalTrials.gov Identifier:	NCT00396851

Purpose

The study plans to compare the glucose-lowering effect of gurmar, a herbal preparation, with metformin in patients with type 2 diabetes

Condition	Intervention
Type 2 Diabetes Mellitus	Drug: Gurmar Drug: Metformin

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: Diabetes

Drug Information available for: Gymnema sylvestre Metformin Metformin hydrochloride

Further study details as provided by Postgraduate Institute of Medical Education and Research:

Estimated Enrollment:	100
Study Start Date:	January 2007

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00396851

Contacts

Contact: Samir Malhotra, MD, DM

+91-172-27552433

Locations

Sponsors and Collaborators

Postgraduate Institute of Medical Education and Research

Indian Council of Medical Research

International Clinical Epidemiology Network (INCLEN) TRUST

Investigators

Study Chair:	Deepak Bhasin, MD,DM	PGIMER
Principal Investigator:	Anil Bhansali	PGIMER

More Information

No publications provided

Study ID Numbers:	Pharma 6/700
Study First Received:	November 6, 2006
Last Updated:	November 6, 2006
ClinicalTrials.gov Identifier:	NCT00396851 History of Changes
Health Authority:	India: Ministry of Health

Additional relevant MeSH terms:

Hypoglycemic Agents
Metabolic Diseases
Physiological Effects of Drugs
Metformin
Diabetes Mellitus, Type 2

Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 09, 2009